 |
|
New Herceptin results confirm impressive reduction in risk of cancer returning
September 14, 2005New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer. Fourth large phase III trial establishes and confirms Herceptin's superiority to chemotherapy alone
New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer
Fourth large phase III trial establishes and confirms Herceptin's superiority to chemotherapy alone
Roche announced today that a fourth large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin (trastuzumab) to chemotherapy significantly reduces the risk of cancer coming back compared to chemotherapy alone. This study follows three earlier phase III studies which also confirmed Herceptin's superiority to chemotherapy alone in early-stage breast cancer. HER2-positive breast cancer is a particularly aggressive form of the disease which affects approximately 20 - 30% of women with breast cancer.[a]
"The results from Herceptin's development programme in early breast cancer have been nothing less than remarkable, commented William M. Burns, CEO of Roche's Pharmaceuticals Division. "Four large trials in the past five months have delivered outstanding efficacy and safety from a vast patient pool and with a variety of treatment regimens, more than two years earlier than planned. Roche, the medical community and regulatory authorities around the world are urgently working together to secure access to Herceptin for early-stage HER2-positive breast cancer patients as soon as possible, and filing in Europe could happen as early as the beginning of 2006.\\\
Ketchum
Roche announced today that a fourth large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin (trastuzumab) to chemotherapy significantly reduces the risk of cancer coming back compared to chemotherapy alone. This study follows three earlier phase III studies which also confirmed Herceptin's superiority to chemotherapy alone in early-stage breast cancer. HER2-positive breast cancer is a particularly aggressive form of the disease which affects approximately 20 - 30% of women with breast cancer.[a]
"The results from Herceptin's development programme in early breast cancer have been nothing less than remarkable, commented William M. Burns, CEO of Roche's Pharmaceuticals Division. "Four large trials in the past five months have delivered outstanding efficacy and safety from a vast patient pool and with a variety of treatment regimens, more than two years earlier than planned. Roche, the medical community and regulatory authorities around the world are urgently working together to secure access to Herceptin for early-stage HER2-positive breast cancer patients as soon as possible, and filing in Europe could happen as early as the beginning of 2006.\\\
Ketchum
Herceptin Current Events and Herceptin News RSSFDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Hunting for the Prozac Gene
Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage.
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).
Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.
Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.
Light reveals breast tumor oxygen status
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.
Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet.
More Herceptin Current Events and Herceptin News Articles
 |
Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer by Robert Bazell (Author) Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear... |
 |
Living Proof Starring: Regina King, Swoosie Kurtz, Amy Madigan, Tom Nowicki, Bernadette Peters Directed By: Dan Ireland Top-rated Lifetime movie! Dr. Dennis Slamon has reached a breakthrough in his career. He has helped to develop a new experimental drug called Herceptin, which he hopes will become a revolutionary treatment in the fight against breast cancer. However, when funding for his project is cut, Slamon must turn to philanthropists Lilly Tartikoff and Ron Perelman to help make his life's most important work a reality. With the backing of his new supporters, Slamon continues to perfect his treatment, but his new drug proves that while it has the ability to give life, it does not work for everyone. This gut-wrenching true story explores one doctor's difficult struggle to find a cancer treatment that can save thousands of lives while giving meaning to his own life. |
|
How Does Herceptin Work? A 3-D Animation by Genentech (Author) This is a DVD book--can be played as a standard DVD or on a computer. | |
 |
Living Proof Starring: Harry Connick Jr., Paula Cale, Angie Harmon, Bernadette Peters, Regina King Directed By: Dan Ireland, Dan Ireland Also With: Cathy M. Frank (Producer), Cathy M. Frank (Producer), Neil Meron (Producer), Neil Meron (Producer), Neil Meron (Producer), Neil Meron (Producer), Vivienne Radkoff (Producer), Vivienne Radkoff (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Ren??e Zellweger (Producer) |
 |
Charlie Rose with Robert Bazell, Larry Norton, Fran Visco & Lois Kasper; John Edgar Wideman (September 28, 1998) First, Robert Bazell, author of Her 2, Dr. Larry Norton, oncologist at Memorial Sloan-Kettering Cancer Center, Lois Kasper of S.H.A.R.E, currently undergoing treatment for breast cancer with Herceptin, and Fran Visco, Chairwoman of the National Breast Cancer Coalition, sit down to talk about Herceptin as a treatment for breast cancer. Finally, John Edgar Wideman, known for his acclaimed stories of African-American life, discusses his new book, Two Cities- A Love Story, about his love of Philadelphia and Pittsburgh. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
Expanded use of Herceptin.(Updates): An article from: FDA Consumer by Gale Reference Team (Author) This digital document is an article from FDA Consumer, published by Thomson Gale on March 1, 2007. The length of the article is 454 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Expanded use of Herceptin.(Updates) Author: Gale Reference Team Publication: FDA Consumer (Magazine/Journal) Date: March 1, 2007 Publisher: Thomson Gale Volume: 41 Issue: 2 Page: 4(2) Distributed by Thomson Gale | |
|
Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) by D. Khayat (Editor) The humanised monoclonal antibody Herceptin[registered] targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30 per cent of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin[registered] have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin[registered] that have been performed... | |
|
Herceptin: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed. by Lee Paradise (Author) Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. | |
|
The hype over Herceptin.(LETTERS)(Letter to the editor): An article from: Kai Tiaki: Nursing New Zealand by Jo Fitzpatrick (Author) This digital document is an article from Kai Tiaki: Nursing New Zealand, published by New Zealand Nurses' Organisation on March 1, 2009. The length of the article is 655 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: The hype over Herceptin.(LETTERS)(Letter to the editor) Author: Jo Fitzpatrick Publication: Kai Tiaki: Nursing New Zealand (Magazine/Journal) Date: March 1, 2009 Publisher: New Zealand Nurses' Organisation Volume: 15 Issue: 2 Page: 4(2) Article Type: Letter to the editor Distributed by Gale, a part of Cengage... | |
|
Early Herceptin use cuts breast Ca recurrence in half: 'stunning' results when used as adjuvant tx.(News): An article from: OB GYN News by Jane Salodof MacNeil (Author) This digital document is an article from OB GYN News, published by Thomson Gale on June 15, 2005. The length of the article is 932 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Early Herceptin use cuts breast Ca recurrence in half: 'stunning' results when used as adjuvant tx.(News) Author: Jane Salodof MacNeil Publication: OB GYN News (Magazine/Journal) Date: June 15, 2005 Publisher: Thomson Gale Volume: 40 Issue: 12 Page: 1(2) Distributed by Thomson... |
| © 2009 BrightSurf.com |